Pre-clinical studies demonstrated that SM17 selectively binds to human IL-17RB, leading to inhibition of alarmin-induced IL-5, IL-9 and IL-13 production, and restoration of Th2 immunity and skin pathology in an animal model of atopic dermatitis (AD) (25). The gene discussed is IL17RB; the disease is Alzheimer disease.